TITLE

Ontario's law curbing the cost of generic drugs sparks changes for pharmacies and other Canadian buyers

AUTHOR(S)
Silversides, Ann
PUB. DATE
August 2009
SOURCE
CMAJ: Canadian Medical Association Journal;8/4/2009, Vol. 181 Issue 3/4, pE43
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on Ontario's medical law which has curbed the cost of generic drugs and has sparked changes for pharmacies and other Canadian buyers. Reportedly, Canadian prices for generic drugs, copies of brand-name drugs have lost patent protection due to some complicated causes. It notes that Ontario's legislation has aimed to decrease the drug benefit plan costs in the province. INSET: Private payers "wake up" to drug price gap.
ACCESSION #
43397001

 

Related Articles

  • Lawmakers still debating PDUFA IV. Wechsler, Jill // Formulary;Jun2007, Vol. 42 Issue 6, p411 

    The article provides updates about the Prescription Drug User Fee Act (PDUFA) in the U.S., which is set to expire on September 30, 2007. According to the author, the reauthorization of the bill could be delayed if issues surrounding generic drugs and drug importation create an impasse on the...

  • Drug Product Selection: The Florida Experience. Vuturo, George J.; Krischer, Jeffrey P.; McCormick, William C. // American Journal of Public Health;May80, Vol. 70 Issue 5, p479 

    Abstract: Drug product selection, the act of selecting and dispensing a lower cost generically equivalent product to that prescribed, is made possible in 46 states through recently enacted legislation. Florida's legislation is unique in that it requires pharmacists to product select under...

  • State and federal legislation in personalized medicine. Raich, Theresa; Irwin, Joyce // MLO: Medical Laboratory Observer;Aug2007, Vol. 39 Issue 8, p48 

    The article reports on state and federal legislation related to personalized medicine in the U.S. It says that growing state and federal legislative interest is evident in legislative activity in state and federal governments, particularly on the approval and uses of personalized-medicine...

  • Reintroduced Bill Would Prohibit Pay-for-Delay Settlements. Greb, Erik // Pharmaceutical Technology;Mar2009, Vol. 33 Issue 3, p35 

    The article reports on the reintroduction of the Preserve Access to Affordable Generics Act by Senior Senate Judiciary Committee members Herb Kohl and Chuck Grassley in the U.S. The bill would prevent patent settlements of pharmaceutical companies wherein manufacturers of branded drugs pay...

  • Cough syrup laws could mean big OTC headache. Johnsen, Michael // Drug Store News;6/25/2007, Vol. 29 Issue 8, p82 

    The article reports on the legislation that could put some restrictions on the selling of Dextromethorphan (DXM) in drug stores in the U.S. Most drug store retailers are voluntarily restricting sales of DXM to minors with an ID prompt at the checkout registers whenever any DXM product is...

  • The Long Road to Generics.  // Pharmaceutical Executive;Jan2005, Vol. 25 Issue 1, pS7 

    This article reports that Mexico was the first Latin American country to pass a law in order to stimulate and regulate the development of quality and efficient generics, qualified as Genericos Intercambiables or Gis (for Inter Exchangeable Generic). The law was very clear in its definitions: GIs...

  • The Irony of Drug Product Selection. Wertheimer, Albert I. // American Journal of Public Health;May80, Vol. 70 Issue 5, p473 

    The author reflects on the enactment of the Drug Product Selection legislation in the U.S. The legislation allows the choice of the source of generic drug to be left in the hands of the pharmacist. He points out that it is ironic that the pharmacists have to look refuge through legislation which...

  • Patent law draws fire.  // R&D Magazine;Apr2005, Vol. 47 Issue 4, p13 

    Reports on the passage of a legislation by the Indian Parliament that will make it illegal for domestic companies to manufacture generic copies of patented drugs, effective in March 2005. Provisions of the law; Significance of the passage of the bill, according to Harvey Bale, director-general...

  • New Legislations on Generics and Biosimilars Brewing in Congress. Buffery, Dalia // American Health & Drug Benefits;Apr/May2009, Vol. 2 Issue 3, p120 

    The article reports on various bills being introduced in the 111th Congress, which proposes new legislations on generic drugs and biosimilars in the U.S. The H.R. 1706 bill, Protecting Access to Generic Drugs Act, introduced by Representative Bobby Rush, proposes to prohibit brand name drug...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics